SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (Nasdaq: SGEN) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, the Company announced that the U.S. Food and Drug Administration had enforced a clinical hold or partial clinical hold on initial stage trials of the Company's experimental cancer drug, vadastuximab talirine, to assess any possible risk of hepatotoxicity. The Company mentioned that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

When this news was released to the public, the value of Seattle Genetics dropped, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170120005489/en/

Lundin Law PC
Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

[email protected]

Source: Lundin Law PC